Neurosense Therapeutics Ltd (NRSN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $6.35 (-5.51%), Market cap $0.03B, 52-week low–high $0.69 ~ $2.49.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the
Financial statements, price targets, institutional (13F) holdings and related news for Neurosense Therapeutics Ltd are updated in real time on BlackAll Trade.
Neurosense Therapeutics Ltd trades at $6.35 (-5.51%). Real-time quotes and charts are available on BlackAll Trade.
Neurosense Therapeutics Ltd has a market cap of about $0.03B.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and i